Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...6566676869707172737475...143144»
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    [VIRTUAL] Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small cell lung cancer (aNSCLC): A pooled analysis of 6 randomized trials (ePoster Display) -  Feb 24, 2021 - Abstract #ELCC2021ELCC_382;    
    P2, P2/3,
    Pts assigned to CT arms or combination arms of CT with other non-cytotoxic drugs (rofecoxib in GECO and cetuximab in CALC1), that had received at least one cycle of CT and for whom at least one toxicity case report form was available, were considered eligible for the analysis...At multivariable OS analysis, CIN was significantly predictive of prognosis although its prognostic value was entirely driven by severe CIN (HR of death 0.71; 95%CI: 0.53–0.95) while it was not evident with mild CIN (HR 1.21; 95%CI: 0.92–1.58). Consistent results were observed in the out-of-landmark group (including 957 pts), where both severe and mild CIN were significantly associated with a reduced risk of death.Conclusions This pooled analysis of six large trials of aNSCLC treatment shows a significant improvement of OS in pts developing CIN, particularly in those developing severe CIN, confirming our previous findings
  • ||||||||||  Bavencio (avelumab) / EMD Serono, Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    [VIRTUAL] First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC) (ePoster Display) -  Feb 24, 2021 - Abstract #ELCC2021ELCC_318;    
    P2a
    Methods This phase IIa study (NCT03717155) enrolled patients with previously untreated histologically confirmed, stage IV, recurrent or metastatic, squamous NSCLC without EGFR/ALK mutations. Patients received avelumab 800 mg (days 1 and 8); cetuximab 250 mg/m2 (day 1) and 500 mg/m2 (day 8); cisplatin 75 mg/m2 (day 1); and gemcitabine 1250 mg/m2 (days 1, 8) for 4 × 3-week cycles followed by avelumab 800 mg and cetuximab 500 mg/m2 maintenance every 2 weeks until progression, unacceConclusions The combination of avelumab, cetuximab, cisplatin and gemcitabine showed clinical activity and a manageable safety profile with no additional safety signals for avelumab or cetuximab.
  • ||||||||||  Biomarker, Trial completion date, Metastases:  MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) -  Feb 24, 2021   
    P2,  N=609, Active, not recruiting, 
    Patients received avelumab 800 mg (days 1 and 8); cetuximab 250 mg/m2 (day 1) and 500 mg/m2 (day 8); cisplatin 75 mg/m2 (day 1); and gemcitabine 1250 mg/m2 (days 1, 8) for 4 × 3-week cycles followed by avelumab 800 mg and cetuximab 500 mg/m2 maintenance every 2 weeks until progression, unacceConclusions The combination of avelumab, cetuximab, cisplatin and gemcitabine showed clinical activity and a manageable safety profile with no additional safety signals for avelumab or cetuximab. Trial completion date: Oct 2020 --> Mar 2021
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal, IO biomarker:  Therapeutic options for advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer: a Bayesian network secondary analysis. (Pubmed Central) -  Feb 24, 2021   
    For PFS regarding the EGFR genomic aberration status, Erlo+Bev, Osi, and Afa were superior for exon 19 deletion status, whereas ET+Bev, Osi, and gefitinib (Gef)+pemetrexed (Peme) were excellent for exon 21 L858Arg mutation status...Osi, Erlo+Bev, and Erlo+Bev+Plat are reasonably recommended to balance PFS and OS, but adverse events should be considered. IT+aVEGFR+Plat shows potential superiority, but more clinical evidence is needed.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Review, Journal, IO biomarker:  Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. (Pubmed Central) -  Feb 24, 2021   
    Although cures remain uncommon, more patients can anticipate extended survival. Genomic profiling allows treatment selection so that more patients derive benefit and fewer are exposed to toxicity from ineffective therapies.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, dinaciclib (PS-095760) / Ligand, Merck (MSD)
    Journal, IO biomarker:  Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib. (Pubmed Central) -  Feb 23, 2021   
    Comparable, although less pronounced effects were seen in HNSCC upon Cetuximab and conventional drugs (i.e., 5-fluorouracil, Gemcitabine)...Our comprehensive data imply inhibition of the TRP catabolism by Dinaciclib, while conventional chemotherapeutics tend to activate this pathway. These data point to limitations of conventional therapy and highlight the potential of targeted therapies to interfere with the cells' metabolism more than anticipated.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Review, Journal:  Anti-EGFR therapies in nasopharyngeal carcinoma. (Pubmed Central) -  Feb 18, 2021   
    Targeting EGFR therapies including monoclonal antibodies and EGFR tyrosine kinase inhibitors (EGFR-TKIs), offer different benefits and toxicities for patients with NPC. Herein, we summarize the clinical evidence of anti-EGFR therapies in the management of NPC and provide a direction for the treatment and research of NPC in the future.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Beyond conventional chemotherapy, targeted therapy and immunotherapy in squamous cell cancer of the oral cavity. (Pubmed Central) -  Feb 17, 2021   
    Triple drug metronomic chemotherapy (methotrexate, celecoxib, and erlotinib) is still under development with promising data from pilot studies...Both in vivo and in-vitro data suggests that numerous drugs like anthelmintics, DMARDs, antimalarials can be repurposed for Head and Neck Cancers. However, there is a dearth of clinical studies reported till date.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
    Journal:  Encorafenib (Braftovi) for metastatic colorectal cancer. (Pubmed Central) -  Feb 17, 2021   
    The patient presented with IgE antibodies specific to alpha-gal, which is the most common epitope linked to red meat allergy induced by tick bites. No abstract available
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  KLF4 p.A472D Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer. (Pubmed Central) -  Feb 13, 2021   
    These results suggest that the KLF4 p.A472D may contribute to cetuximab resistance in patients with mCRC and thus, it may serve as a new biomarker in clinical application. Monitoring somatic mutations related to cetuximab resistance in mCRC patients through ctDNA may provide real-time insights for clinical reference and treatment planning.
  • ||||||||||  subasumstat (TAK-981) / Takeda
    Trial completion date, Trial primary completion date:  Intratumoral Microdosing of TAK-981 in Head and Neck Cancer (clinicaltrials.gov) -  Feb 12, 2021   
    P1,  N=12, Recruiting, 
    Trial completion date: Jan 2021 --> Jun 2021 Trial completion date: Dec 2020 --> Mar 2021 | Trial primary completion date: Dec 2020 --> Mar 2021
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
    Clinical, Journal:  HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer. (Pubmed Central) -  Feb 11, 2021   
    In 48% and 71% of the cases, there were discordance in the expression of EGFR or one or more HER family members in paired primary and related metastatic tumours, respectively. Our results implicate the importance of a large prospective investigation of the expression level and predictive value of not only the therapeutic target (i.e., EGFR protein) but also HER2 and other HER family members as therapeutic targets, or for response to therapy with anti-EGFR mAbs and other forms of HER inhibitors, in both the primary tumours and metastatic sites in mCRC.
  • ||||||||||  Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date:  QUantitative Assessment of Swallowing After Radiation (QUASAR) (clinicaltrials.gov) -  Feb 9, 2021   
    P=N/A,  N=42, Recruiting, 
    These findings clearly show that the use of LIFUS agents with high-performance imaging in different therapeutic settings will have extensive potential for future biomedical applications. Not yet recruiting --> Recruiting | Trial completion date: Dec 2023 --> Sep 2023 | Initiation date: Jun 2020 --> Sep 2020 | Trial primary completion date: Dec 2022 --> Sep 2022
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal, IO biomarker:  Dual inhibition of RNAi therapeutic miR-26a-5p targeting cMet and immunotherapy against EGFR in endometrial cancer treatment. (Pubmed Central) -  Feb 9, 2021   
    Furthermore, the dual therapeutic effect of miR-26a-5p and EGFR monoclonal antibody cetuximab was confirmed in vivo and in vitro...RNAi therapeutic miR-26a-5p suppressed the progression of EC through regulating the cMet/HGF pathway. The dual therapy using RNA interference and neutralizing antibody simultaneously blocked tumor targets, including cMet and EGFR, thus providing a novel approach for overcoming the resistance to the inhibitors against a single target in EC treatment.